Hélène M Faessel

Title: Hélène M Faessel: Innovator in Prostate Cancer Treatment

Introduction

Hélène M Faessel is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of prostate cancer. With a total of 3 patents, his work has the potential to impact many lives.

Latest Patents

Faessel's latest patents focus on innovative methods for treating prostate cancer. One method involves administering at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea once daily to patients in need. Another method includes an oral load dose formulation ranging from 240 mg to 480 mg, followed by a maintenance dose of 80 mg to 160 mg of the same compound. These advancements represent a significant step forward in prostate cancer treatment.

Career Highlights

Throughout his career, Faessel has worked with prominent companies in the pharmaceutical industry. He has been associated with Sumitomo Pharma Switzerland GmbH and Takeda Pharmaceutical Company Limited. His experience in these organizations has contributed to his expertise in developing effective cancer treatments.

Collaborations

Faessel has collaborated with notable colleagues, including Vijaykumar Reddy Rajasekhar and Brendan Mark Johnson. These partnerships have likely enhanced his research and development efforts in the field of oncology.

Conclusion

Hélène M Faessel's innovative work in prostate cancer treatment showcases his dedication to improving patient outcomes. His patents and collaborations reflect a commitment to advancing medical science and providing new hope for those affected by cancer.